Short-term safety and efficacy of escalating doses of atorvastatin for dyslipidemia in children with predialysis chronic kidney disease stage 2–5

Background Dyslipidemia is a potentially modifiable risk factor in patients with chronic kidney disease (CKD). Information on the safety and efficacy of statins in pediatric CKD is limited. Methods Patients with CKD stage 2–5 and aged 5–18 years with low-density lipoprotein cholesterol (LDL-C) > ...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric nephrology (Berlin, West) West), 2023-08, Vol.38 (8), p.2763-2770
Hauptverfasser:	Ramesh, Punitha Lakxmi, Khandelwal, Priyanka, Lakshmy, R., Sinha, Aditi, Bagga, Arvind, Hari, Pankaj
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Anticholesteremic Agents Atorvastatin Atorvastatin - adverse effects Care and treatment Child Children Cholesterol Cholesterol, LDL Chronic kidney failure Complications and side effects Diseases Dyslipidemia Dyslipidemias Dyslipidemias - complications Dyslipidemias - diagnosis Dyslipidemias - drug therapy Heptanoic Acids - adverse effects High density lipoprotein Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Kidney diseases Lipids Low density lipoprotein Medicine Medicine & Public Health Metabolic disorders Nephrology Original Article Patient outcomes Pediatrics Pyrroles - adverse effects Renal Insufficiency, Chronic - chemically induced Renal Insufficiency, Chronic - complications Risk factors Statins Treatment Outcome Urology What’s New in Chronic Kidney Disease
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!